Patent US2297833A successfully refreshed from Google Patents.
Patent US5670488A successfully refreshed from Google Patents.
US5670488A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Adenovirus vector for gene therapy
Assignee: Genzyme Corp
•
Filing: 1993-10-13
•
Granted: 1997-09-23
•
Expires: 2013-10-13
Abstract
Abstract Gene Therapy vectors, which are especially useful for cystic fibrosis, and methods for using the vectors are disclosed.
Inventors
- 👤 Richard J. Gregory
- 👤 Donna Armentano
- 👤 Larry A. Couture
- 👤 Alan E. Smith
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 08:55
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K48/00; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4712; A61K38/00; C12N2710/00; C12N2710/00011; C12N2710/10011; C12N2710/10311; C12N2710/10341; C12N2710/10343; C12N2830/00; C12N2830/42; C12N2840/00; C12N2840/20; C12N2840/203
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
52 words
An adenoviral vector comprising an adenovirus genome from which one or more of the E4 open reading frames has been deleted, but retaining sufficient E4 sequences to promote virus replication in vitro, and additionally comprising a DNA sequence of interest operably linked to expression control sequences and inserted into said adenoviral genome.
Claim 2
Dependent Claim
52 words
An adenoviral vector comprising an adenovirus genome from which one or more of the E4 open reading frames has been deleted, but retaining sufficient E4 sequences to promote virus replication in vitro, and additionally comprising a DNA sequence of interest operably linked to expression control sequences and inserted into said adenoviral genome.
Claim 3
Dependent Claim
18 words
The vector of claim 1 wherein a PGK promoter is operably linked to the DNA sequence of interest.
Claim 4
Dependent Claim
19 words
The vector of claim 1 from which the Ela and Elb regions of the adenovirus genome have been deleted.
Claim 5
Dependent Claim
17 words
The vector of claim 1 from which the E3 region of the adenovirus genome has been deleted.
Claim 6
Dependent Claim
22 words
The adenoviral vector of claim 1 in which open reading frame 6 of the E4 region is retained in the adenovirus genome.
Claim 7
Dependent Claim
22 words
The adenoviral vector of claim 1 in which open reading frame 3 of the E4 region is retained in the adenovirus genome.
Claim 8
Dependent Claim
16 words
The adenoviral vector of claim 1 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.
Claim 9
Dependent Claim
16 words
The adenoviral vector of claim 2 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.
Claim 10
Dependent Claim
16 words
The adenoviral vector of claim 3 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.
Claim 11
Dependent Claim
23 words
The adenoviral vector of claim 3 wherein the DNA sequence is inserted into the deleted Ela and Elb regions of the adenoviral genome.
Claim 12
Dependent Claim
16 words
The adenoviral vector of claim 5 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.
Claim 13
Dependent Claim
19 words
The adenoviral vector of claim 6 wherein a cytomegalovirus promoter is operably linked to the DNA sequence of interest.
Claim 14
Independent Claim
118 words
A method for providing cystic fibrosis transmembrane conductance regulator protein to airway epithelial cells of a cystic fibrosis patient comprising administering directly to airway epithelial cells of the patient an adenoviral vector, said vector comprising an adenovirus genome from which one or more E4 open reading frames has been deleted, but retaining sufficient E4 sequences to promote virus replication in vitro, and additionally comprising a DNA sequence encoding cystic fibrosis transmembrane regulator protein operably linked to expression control sequences and inserted into the E1 region said adenoviral genome, under conditions whereby the DNA sequence encoding cystic fibrosis transmembrane regulator protein is expressed and a functional chloride ion channel is produced in the airway epithelial cells of the patient.
Claim 15
Independent Claim
118 words
A method for providing cystic fibrosis transmembrane conductance regulator protein to airway epithelial cells of a cystic fibrosis patient comprising administering directly to airway epithelial cells of the patient an adenoviral vector, said vector comprising an adenovirus genome from which one or more E4 open reading frames has been deleted, but retaining sufficient E4 sequences to promote virus replication in vitro, and additionally comprising a DNA sequence encoding cystic fibrosis transmembrane regulator protein operably linked to expression control sequences and inserted into the E1 region said adenoviral genome, under conditions whereby the DNA sequence encoding cystic fibrosis transmembrane regulator protein is expressed and a functional chloride ion channel is produced in the airway epithelial cells of the patient.
Claim 16
Dependent Claim
23 words
The method of claim 13 wherein open reading frame 6 of the E4 region of the adenovirus genome is retained in the vector.
Claim 17
Dependent Claim
20 words
The method of claim 13 wherein the expression control sequences operably linked to the DNA sequence comprise the PGK promoter.
Claim 18
Dependent Claim
22 words
The method of claim 13 in which the Ela and Elb regions of the adenovirus genome of the vector have been deleted.
Claim 19
Dependent Claim
20 words
The method of claim 13 in which the E3 region of the adenovirus genome of the vector has been deleted.
Claim 20
Dependent Claim
23 words
The method of claim 13 wherein open reading frame 3 of the E4 region of the adenovirus genome is retained in the vector.
Claim 21
Dependent Claim
20 words
The method of claim 18 wherein the expression control sequences operably linked to the DNA sequence comprise a cytomegalovirus promoter.
References Cited (Backward Citations)
US4920209A
Cited
EP0185573A1
Cited
WO1991002796A1
Cited
WO1991010734A1
Cited
EP0446017A1
Cited
WO1993012240A1
Cited
WO1993012756A2
Cited
WO1993019191A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-09-22 | 2001-03-24 | 2001-09-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-09-22 | 2005-03-24 | 2005-09-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-09-22 | 2009-03-24 | 2009-09-23 | $7700.00 | Window Closed / Lapsed |